CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
about
Influence of immunoglobulin isotype on therapeutic antibody functionNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerLymphoma Immunotherapy: Current StatusImmune Modulation in Hematologic MalignanciesEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityNatural killer cell biology: an update and future directionsModulation of GITR for cancer immunotherapy4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesCD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses4-1BB agonism: adding the accelerator to cancer immunotherapyMechanisms of action of therapeutic antibodies for cancerComplement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsNK cell-based immunotherapy for malignant diseases.Targeting CD137 enhances the efficacy of cetuximab.Targeting secondary immune responses to cetuximab: CD137 and the outside story.Combination immunotherapy: a road map.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodiesConformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.Agonist antibodies to TNFR molecules that costimulate T and NK cellsNKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Haematological malignancies: at the forefront of immunotherapeutic innovation.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptorsUnlicensed NK cells target neuroblastoma following anti-GD2 antibody treatmentImmunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functionsIdentification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytesAnti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.Combination immune therapies to enhance anti-tumor responses by NK cells.
P2860
Q26772080-90311F87-DA66-4EF2-9E0D-7D398317AE8AQ26772347-84C1D6D5-FEF3-46BA-A3DE-369A917A06FBQ26774678-3F513C01-C5E2-4AEF-8B6F-33FDED065673Q26782902-829DA72C-33B0-45FC-A60E-5C6146DC6FDDQ26796307-F3C66CE1-C6D5-436E-B47B-D9FD3BF1EC97Q26796313-1083492C-E65E-432E-8792-E6434F7E9831Q26830512-7F1AB793-486E-4CF2-B3F1-17B9FD19F78CQ26853557-EA8A7249-B111-40E5-848A-07CBD3D94F30Q27012963-91BAC8F8-7CDB-46D9-931F-C065C616C9E2Q27694769-C786CA7F-3DC0-492D-9148-63746AC66A1FQ28072933-DD8DC4B2-74C7-445C-8BF2-AA682D785F2DQ28079622-8B928F29-AFE1-4A57-8924-15131D870A6BQ28385366-A3D663A5-D657-42B0-A0D3-55FA12C7928CQ30356145-1137992B-1AA5-4907-BF70-B09116125469Q30456436-18063C6C-4F8B-4639-822E-B3DE60471C48Q33434322-1C613AD0-9EA8-4280-8AEC-B1B0C25FEA00Q33809528-76F9E90C-E6F0-46AB-BCE5-F2A0F880937FQ33827433-C5B0E51F-9514-4636-8EFF-FF2A7111A648Q33872482-0827EAC2-19FC-4208-B8B0-0E8938F61F66Q33872496-273A1380-748C-4185-B8C2-0E08DC5E0E79Q34552128-1C1880F4-5775-415B-9C2D-B8C59C80A8D5Q34598149-34B0B0AE-0CA3-4BAC-B174-20F8C13CF30AQ34978570-C4F35335-3F89-463E-B3BE-3EFD661BEED1Q35031732-F56727F9-8713-4CB1-AE36-D7AB9E04363EQ35153794-D533B1D3-F24E-4490-B4BE-395337134933Q35427446-BD78B61A-8EA5-4A79-8A12-78944B089C84Q35506745-46BF9AF8-873E-430C-955D-F0A209C50D9DQ35764479-56CCC76B-7FB5-4146-9305-08E4ABDE4859Q35780315-BF4A90C8-C49B-431C-8B94-ABFD66966E0AQ35880618-79050A73-0694-4859-A74C-3CCD6E34F59AQ35922726-7438E15D-0337-4790-ACFD-BF963D89EA22Q36102906-1878D154-E861-4650-85BB-35E4012A5498Q36190723-73542170-6E71-476A-9042-F6DD410CCC2DQ36220613-8D85C1F5-3B04-4129-A2FB-F10688F87DA9Q36387028-C45C9CC3-03DC-45FE-863F-A7A70CA6C6FCQ36597479-F94647BD-E1BF-47CB-BCB6-3D12FAB07F9CQ36752738-137E41E1-81DC-46DC-8AA7-F99EA97F7169Q37012676-464CD2AA-AFCC-4504-AEA4-4DA4453D1537Q37222143-6D131944-0065-4CB0-B9EC-98E4E6C7DA51Q37408550-2098D5F4-C1AC-439E-9B99-B76CD4636D0D
P2860
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@ast
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@en
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@nl
type
label
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@ast
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@en
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@nl
prefLabel
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@ast
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@en
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@nl
P2093
P2860
P1433
P1476
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
@en
P2093
Antonia Müller
Ash A Alizadeh
Debra Czerwinski
Holbrook E Kohrt
Josh Brody
Kipp Weiskopf
Lieping Chen
Mark P Chao
Matthew J Goldstein
Roch Houot
P2860
P304
P356
10.1182/BLOOD-2010-08-301945
P407
P577
2010-12-30T00:00:00Z